We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Will ‘Streamline’ Authorizations of COVID-19 Vaccines Revamped for New Strains
FDA Will ‘Streamline’ Authorizations of COVID-19 Vaccines Revamped for New Strains
A “streamlined” process for authorizing COVID-19 vaccines modified to address significant new coronavirus strains is in the works to enable the FDA to quickly react to significant viral mutations, said Center for Biologics Evaluation and Research (CBER) Director Peter Marks.